Your browser doesn't support javascript.
loading
Interaction of tau with HNRNPA2B1 and N6-methyladenosine RNA mediates the progression of tauopathy.
Jiang, Lulu; Lin, Weiwei; Zhang, Cheng; Ash, Peter E A; Verma, Mamta; Kwan, Julian; van Vliet, Emily; Yang, Zhuo; Cruz, Anna Lourdes; Boudeau, Samantha; Maziuk, Brandon F; Lei, Shuwen; Song, Jaehyup; Alvarez, Victor E; Hovde, Stacy; Abisambra, Jose F; Kuo, Min-Hao; Kanaan, Nicholas; Murray, Melissa E; Crary, John F; Zhao, Jian; Cheng, Ji-Xin; Petrucelli, Leonard; Li, Hu; Emili, Andrew; Wolozin, Benjamin.
Afiliação
  • Jiang L; Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.
  • Lin W; Center for Network Systems Biology, Boston University School of Medicine, Boston, MA 02118, USA.
  • Zhang C; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA.
  • Ash PEA; Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.
  • Verma M; Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.
  • Kwan J; Center for Network Systems Biology, Boston University School of Medicine, Boston, MA 02118, USA.
  • van Vliet E; Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.
  • Yang Z; Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.
  • Cruz AL; Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.
  • Boudeau S; Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.
  • Maziuk BF; Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.
  • Lei S; Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.
  • Song J; Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.
  • Alvarez VE; Department of Neurology, Boston University School of Medicine, Boston, MA 02118, USA.
  • Hovde S; Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI 48824, USA.
  • Abisambra JF; Department of Neuroscience, University of Florida, Gainesville, FL 32611, USA.
  • Kuo MH; Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI 48824, USA.
  • Kanaan N; Department of Translational Science and Molecular Medicine, College of Human Medicine, Michigan State University, Grand Rapids, MI 49503, USA.
  • Murray ME; Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.
  • Crary JF; Department of Pathology, Mount Sinai Medical Center, New York, NY 10029, USA.
  • Zhao J; Department of Electrical and Computer Engineering, Boston University, Boston, MA 02459, USA.
  • Cheng JX; Department of Electrical and Computer Engineering, Boston University, Boston, MA 02459, USA.
  • Petrucelli L; Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.
  • Li H; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA.
  • Emili A; Center for Network Systems Biology, Boston University School of Medicine, Boston, MA 02118, USA.
  • Wolozin B; Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA; Department of Neurology, Boston University School of Medicine, Boston, MA 02118, USA; Center for Neurophotonics, Boston University, Boston, MA 02215, USA; Center for Systems Neurosc
Mol Cell ; 81(20): 4209-4227.e12, 2021 10 21.
Article em En | MEDLINE | ID: mdl-34453888
ABSTRACT
The microtubule-associated protein tau oligomerizes, but the actions of oligomeric tau (oTau) are unknown. We have used Cry2-based optogenetics to induce tau oligomers (oTau-c). Optical induction of oTau-c elicits tau phosphorylation, aggregation, and a translational stress response that includes stress granules and reduced protein synthesis. Proteomic analysis identifies HNRNPA2B1 as a principle target of oTau-c. The association of HNRNPA2B1 with endogenous oTau was verified in neurons, animal models, and human Alzheimer brain tissues. Mechanistic studies demonstrate that HNRNPA2B1 functions as a linker, connecting oTau with N6-methyladenosine (m6A) modified RNA transcripts. Knockdown of HNRNPA2B1 prevents oTau or oTau-c from associating with m6A or from reducing protein synthesis and reduces oTau-induced neurodegeneration. Levels of m6A and the m6A-oTau-HNRNPA2B1 complex are increased up to 5-fold in the brains of Alzheimer subjects and P301S tau mice. These results reveal a complex containing oTau, HNRNPA2B1, and m6A that contributes to the integrated stress response of oTau.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: RNA / Adenosina / Córtex Cerebral / Processamento Pós-Transcricional do RNA / Proteínas tau / Ribonucleoproteínas Nucleares Heterogêneas Grupo A-B / Doença de Alzheimer Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Aged / Aged80 / Animals / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: RNA / Adenosina / Córtex Cerebral / Processamento Pós-Transcricional do RNA / Proteínas tau / Ribonucleoproteínas Nucleares Heterogêneas Grupo A-B / Doença de Alzheimer Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Aged / Aged80 / Animals / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article